A tailored dose of tenofovir could reduce its impact on bone mass in HIV Type 1-infected children and adolescents: a report from 5 years of clinical experience.
Rosso
Raffaella
R
Parodi
Arianna
A
Torrisi
Chiara
C
De Terlizzi
Francesca
F
Viscoli
Claudio
C
Vignolo
Marina
M
D000225:Adenine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000293:Adolescent; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects / Q000379:methods; D001842:Bone and Bones / Q000502:physiology*; D002113:Calcification, Physiologic / Q000187:drug effects*; D002648:Child; D002675:Child, Preschool; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000302:isolation & purification; D006801:Humans; D008297:Male; D063065:Organophosphonates / Q000008:administration & dosage* / Q000009:adverse effects*; D000068698:Tenofovir
D019380:Anti-HIV Agents; D063065:Organophosphonates; D000068698:Tenofovir; D000225:Adenine